Method of Treatment Claims That Incorporate Inventive Steps Are Not Invalid Under 35 U.S.C. § 101

Sep 1, 2016

Reading Time : 2 min

Vanda’s claims at issue were directed to methods of treating patients with schizophrenia or a schizoaffective disorder by administering a particular dose of the compound iloperidone, where the correct dose is determined based on the results of genetic testing. During development of iloperidone, Vanda discovered that patients with a certain genetic mutation in an enzyme called CYP2D6 poorly metabolize iloperidone, and those patients therefore have increased concentrations of iloperidone in their blood. Increased concentrations of iloperidone can lead to serious side effects, including a type of abnormal heart rhythm that can result in sudden death. Vanda’s method claims are based on this discovery and require that genetic testing be performed on a patient before the patient is administered iloperidone to determine whether the patient has a genetic mutation in CYP2D6. If the patient does not have the genetic mutation, the patient receives the maximum dose of the drug. If the patient does have the genetic mutation and is thus a poor metabolizer of the drug, the dose of the drug is reduced by half (thereby reducing the likelihood of experiencing serious side effects).

Roxane argued that Vanda’s method claims are directed to patent-ineligible subject matter because the claims cover a law of nature applied in a routine and conventional way. To decide this issue, the court applied the two-step analysis of Alice Corp. Pty. v. CLS Bank Int’l, 134 S. Ct. 2347 (2014). First, the court determined whether the asserted method claims depend on laws of nature. According to the court, the claims depend on the natural relationship among iloperidone, mutations in CYP2D6 that cause poor metabolism of iloperidone and raise the concentration of the drug in the blood, and the effect of the increased concentration of iloperidone on normal heart rhythms. Thus, the court found that the claims do depend on laws of nature. Second, the court analyzed whether the claims incorporate some additional non-routine or non-conventional step to transform the nature of the claims into patent eligible subject matter. Vanda’s method claims require genetic testing to determine whether a patient has a CYP2D6 mutation, and, based on the results of that testing, determining the appropriate dose of the administered drug. Relying on competing expert testimony, the court found that Roxane failed to prove that the genetic testing required by the claims and the results of that testing were routine or conventional. The court also noted that it found persuasive that the step of adjusting the dose of the drug does not apply to all patients, but only to those with the genetic mutation, such that the dosage step requires applying genetic testing in a highly specified way. The court thus concluded that the combination of elements recited in the claims is sufficient to ensure that the claims are directed to significantly more than just a natural law.

Vanda Pharma. Inc. v. Roxane Labs, Inc., 13-1973, 14-757-GMS (D. Del. August 25, 2016) (Judge Sleet).

Share This Insight

Previous Entries

IP Newsflash

August 11, 2025

In considering a motion to dismiss infringement claims for two related patents, the District of Massachusetts recently held that pre-suit knowledge of a “parent” patent, without more, is insufficient to establish pre-suit knowledge of the “child” patent for purposes of indirect and willful infringement.

...

Read More

IP Newsflash

August 8, 2025

Following a jury verdict finding trade secret misappropriation, the District Court for the District of Massachusetts granted-in-part a plaintiff’s motion for a permanent injunction to prohibit defendants from using plaintiff’s trade secrets. The district court further required defendants to reassign to plaintiff patents and patent applications that disclosed or were derived from plaintiff’s trade secrets as part of its equitable relief.

...

Read More

IP Newsflash

August 6, 2025

In ruling on a recent motion to strike, a judge in the Eastern District of Texas permitted a damages expert to rely on a damages theory based on defendant’s “avoided costs,” holding that this theory did not run afoul of the “entire market value rule.”

...

Read More

IP Newsflash

August 5, 2025

The Federal Circuit recently vacated a decision by the Patent Trial and Appeal Board after concluding that the board’s analysis of licensing evidence offered as a secondary consideration of nonobviousness constituted legal error and was not supported by substantial evidence. According to the court, the board applied a more exacting and improperly heightened nexus standard than is required by law for license evidence.

...

Read More

IP Newsflash

August 5, 2025

A Northern District of California judge recently granted a motion to reconsider his summary judgment ruling that defendant was barred from raising certain “device art” due to IPR estoppel under 35 U.S.C. § 315(e)(2). In the original ruling, the judge adopted the broader rule that IPR estoppel applies to device art that is “materially identical” to patents or printed publications that petitioners raised, or could have raised, in an IPR. Following that ruling, however, the Federal Circuit issued its Ingenico decision adopting the narrower view that IPR estoppel applies only to “grounds” based on patents and printed publications and not to device-based grounds. Citing Ingenico as a “change of law,” defendant moved for reconsideration of the court’s ruling, and the court granted the motion.

...

Read More

IP Newsflash

August 5, 2025

In a recent decision designated as Informative, the USPTO Director determined that the Patent Trial and Appeal Board abused its discretion by instituting two inter partes review proceedings challenging the same patent, based on petitions advancing different constructions of the same claim term. The Director expressed concerns that permitting multiple petitions based on alternative claim constructions effectively circumvents word count limitations, strains board resources, and undermines procedural efficiency.

...

Read More

IP Newsflash

July 25, 2025

Earlier this year, the Federal Circuit’s decision in Qualcomm Inc. v. Apple Inc. (Qualcomm II) raised questions about the extent to which petitioners can rely on applicant admitted prior art (“AAPA”) in inter partes review proceedings.  The Federal Circuit’s recent decision in Shockwave Medical, Inc. v. Cardiovascular Sys., Inc. largely cabins the Qualcomm II decision to its particular facts and makes clear that AAPA can be used as evidence of background knowledge as part of an obviousness argument.

...

Read More

IP Newsflash

July 11, 2025

The Federal Circuit recently reversed a PTAB determination on remand that a patent was obvious over applicant admitted prior art (“AAPA”) in combination with prior art patents, holding that expressly designating AAPA as a “basis” for a ground is improper under 35 U.S.C. § 311(b). In doing so, the Court rejected the PTAB’s “blanket rule” that “AAPA used in combination with prior art patents or printed publications under § 311(b) is ipso facto not the basis or part of the basis of a ground.” Ultimately, while the case clarifies that expressly listing AAPA in an IPR ground is improper, the precise line between proper and improper uses of AAPA in other instances remains unclear.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.